Lineage Announces a Grand Prize of $50,000 for the Food Chain Innovation Challenge
5.9.2024 14:31:00 CEST | Business Wire | Press release
The global winner will receive substantial prize from Lineage and invite to a six-month, executive-led incubator program to help kick start their business
Lineage, Inc. (NASDAQ: LINE) (the “Company”), the world’s largest global temperature-controlled warehouse REIT, today announced additional details of its flagship competition, the Food Chain Innovation Challenge, including members of the judging panels as well as the grand prize.
The challenge of creating impactful solutions for food waste comes at a critical time, as the severely food-insecure population is expected to hit nearly a billion people by 2028. Lineage’s global competition invites students and startups to pitch their innovative technologies or data solutions that address postharvest food waste.
The Food Chain Innovation Challenge will take place in three major locations: London on November 14, and Amsterdam and San Francisco both on November 19. Students, startups and other relevant candidates interested in participating can submit their applications online until September 30.
During each event, participants will present solutions aimed at mitigating food waste to an esteemed regional judging panel. Judges will select a regional winner, who will be awarded a $5,000 cash prize and a spot in the grand final event on December 2. One winner will then be chosen to receive the $50,000 grand prize and an invite into a six-month, executive-led incubator program tailored to their unique business goals.
London
The London event will take place on November 14, 2024, at The Science Museum. Lineage’s Regional Vice President, Clare Walters, will join a panel of distinguished judges including Simon Millard, Director of Food at FareShare; Harriet Lamb, CEO of WRAP; and Paul Randle, from the Cambridge Institute for Sustainable Leaders at Cambridge University. To support the aspiring innovators, ReLondon and FoodCycle are also partnering with the Food Chain Innovation Challenge to provide valuable insights and coaching as applicants refine their pitches.
Amsterdam
The Amsterdam event will take place on November 19, 2024, at The NEMO Science Museum. Lineage’s European President, Harld Peters, will join a panel of distinguished judges including Toine Timmermans, Director of Samen Tegen Voedselverspilling; Enno Masurel, Professor Doctor of Sustainable Entrepreneurship at the Free University Amsterdam; and Esteban Arriaga, CEO of FEBA (European Food Banks Federation).
San Francisco
The San Francisco event will take place on November 19, 2024, at the California Academy of Sciences. Lineage’s Global Chief Operations Officer Jeff Rivera will join a panel of distinguished judges, including Angel Veza, Capital, Innovation, & Engagement Senior Manager at ReFED; Danielle Todd, Founder and Executive Director at Make Food Not Waste; and Michael Wara, Director, Climate and Energy Policy Initiative at Stanford's Woods Institute for the Environment and Senior Director, Policy at the Sustainability Accelerator within the Stanford Doerr School of Sustainability.
Greg Lehmkuhl, President and CEO of Lineage, said: “Lineage is constantly looking at how we improve the global management of food storage, transportation and distribution. Beyond our own operational improvements, the Food Chain Innovation Challenge is a platform for us to support the industry's most promising talent and innovations. By collaborating, we can develop solutions that not only address food waste but also promote sustainable practices for the long term.”
Jeff Rivera, Global Chief Operations Officer at Lineage, added: “Despite producing enough food to feed the planet, hundreds of millions of people face food insecurity every day. At Lineage, we're dedicated to transforming the food supply chain to eliminate waste and feed the world. The Food Chain Innovation Challenge exemplifies this mission, and we’re excited to highlight new solutions and innovations while supporting these entrepreneurs' journeys to turn their ideas into reality.”
At the events, participants will be asked to pitch their existing ideas across four specific areas: reducing food waste, food preservation techniques, access to nutritious food and data-driven insights and analytics.
If you're interested in participating, apply here. For a glimpse into the 2023 Hackathon, the predecessor to The Food Chain Innovation Challenge held in Amsterdam, watch this video. Also, hear insights from last year's winner to get inspired and understand the impact of winning this prestigious challenge.
About Lineage
Lineage, Inc. (NASDAQ: LINE) is the world’s largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84 million square feet and approximately 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us on LinkedIn, Facebook, Instagram, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905272650/en/
Contacts
Media Contact
Media Contact
Christina Wiese
Public Relations Manager
cwiese@onelineage.com
734-608-1855
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom